A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells.

@article{Lakshminarayanan2015AGD,
  title={A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells.},
  author={A. K. Lakshminarayanan and B. Uma Reddy and Nallani Raghav and Vijay Kumar Ravi and Anuj Kumar and Prabal K. Maiti and Anil Sood and Narayanaswamy Jayaraman and Saumitra Das},
  journal={Nanoscale},
  year={2015},
  volume={7 40},
  pages={16921-31}
}
A RNAi based antiviral strategy holds the promise to impede hepatitis C viral (HCV) infection overcoming the problem of emergence of drug resistant variants, usually encountered in the interferon free direct-acting antiviral therapy. Targeted delivery of siRNA helps minimize adverse 'off-target' effects and maximize the efficacy of therapeutic response. Herein, we report the delivery of siRNA against the conserved 5'-untranslated region (UTR) of HCV RNA using a liver-targeted dendritic nano… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-2 of 2 references

Biophys

  • A. Perez, I. Marchan, +4 authors M. Orozco
  • J.,
  • 2007

J

  • J. M. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, D. A. Case
  • Comput. Chem.,
  • 2004

Similar Papers

Loading similar papers…